GlassScriptPhysician profile
John J Damore
NPI 1932167046
$932.21
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $81.57 · 2021: $213.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $273.63 | 2019-2021 | |
| Glaxosmithkline, LLC. | $242.50 | 2019-2021 | |
| Novo Nordisk INC | $132.47 | 2019-2020 | |
| Pfizer INC. | $66.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $65.72 | 2019 | |
| Merck Sharp & Dohme LLC | $47.93 | 2019-2020 | |
| Amarin Pharma, INC. | $36.13 | 2019 | |
| Abbvie INC. | $20.39 | 2021 | |
| Lilly USA, LLC | $20.00 | 2019 | |
| Astellas Pharma US INC | $14.28 | 2019 | |
| Genentech USA, INC. | $12.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Damore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.